Burkitt Lymphoma – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Burkitt Lymphoma – Pipeline Review, H2 2016’, provides an overview of the Burkitt Lymphoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Burkitt Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Burkitt Lymphoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Burkitt Lymphoma

The report reviews pipeline therapeutics for Burkitt Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Burkitt Lymphoma therapeutics and enlists all their major and minor projects

The report assesses Burkitt Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Burkitt Lymphoma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Burkitt Lymphoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Burkitt Lymphoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Arvinas, Inc.

bluebird bio, Inc.

Boehringer Ingelheim GmbH

Constellation Pharmaceuticals, Inc.

Immunomedics, Inc.

Karyopharm Therapeutics, Inc.

Millennium Pharmaceuticals Inc

Patrys Limited

Seattle Genetics, Inc.

Takeda Pharmaceutical Company Limited

Theravectys SA

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Burkitt Lymphoma Overview 8

Therapeutics Development 9

Pipeline Products for Burkitt Lymphoma - Overview 9

Pipeline Products for Burkitt Lymphoma - Comparative Analysis 10

Burkitt Lymphoma - Therapeutics under Development by Companies 11

Burkitt Lymphoma - Therapeutics under Investigation by Universities/Institutes 13

Burkitt Lymphoma - Pipeline Products Glance 14

Clinical Stage Products 14

Early Stage Products 15

Burkitt Lymphoma - Products under Development by Companies 16

Burkitt Lymphoma - Products under Investigation by Universities/Institutes 17

Burkitt Lymphoma - Companies Involved in Therapeutics Development 18

AbbVie Inc 18

Arvinas, Inc. 19

bluebird bio, Inc. 20

Boehringer Ingelheim GmbH 21

Constellation Pharmaceuticals, Inc. 22

Immunomedics, Inc. 23

Karyopharm Therapeutics, Inc. 24

Millennium Pharmaceuticals Inc 25

Patrys Limited 26

Seattle Genetics, Inc. 27

Takeda Pharmaceutical Company Limited 28

Theravectys SA 29

Burkitt Lymphoma - Therapeutics Assessment 30

Assessment by Monotherapy Products 30

Assessment by Target 31

Assessment by Mechanism of Action 33

Assessment by Route of Administration 35

Assessment by Molecule Type 37

Drug Profiles 39

19-3s - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

20-3s - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

alisertib - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

ARV-825 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

bb-2121 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

Cellular Immunotherapy to Target CD19 for ALL - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Cellular Immunotherapy to Target CD30 for Oncology - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

denintuzumab mafodotin - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

E1-3s - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

Epstein-Barr virus vaccine - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

ibrutinib - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

ixazomib citrate - Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

Monoclonal Antibody Conjugate to Target CD20 for Leukemia and Burkitt Lymphoma - Drug Profile 92

Product Description 92

Mechanism Of Action 92

R&D Progress 92

PATLM-1 - Drug Profile 93

Product Description 93

Mechanism Of Action 93

R&D Progress 93

selinexor - Drug Profile 95

Product Description 95

Mechanism Of Action 95

R&D Progress 95

SH-7129 - Drug Profile 113

Product Description 113

Mechanism Of Action 113

R&D Progress 113

SH-7133 - Drug Profile 114

Product Description 114

Mechanism Of Action 114

R&D Progress 114

SH-7139 - Drug Profile 115

Product Description 115

Mechanism Of Action 115

R&D Progress 115

Small Molecules to Inhibit BET for Oncology - Drug Profile 117

Product Description 117

Mechanism Of Action 117

R&D Progress 117

volasertib trihydrochloride - Drug Profile 118

Product Description 118

Mechanism Of Action 118

R&D Progress 118

Burkitt Lymphoma - Dormant Projects 122

Appendix 123

Methodology 123

Coverage 123

Secondary Research 123

Primary Research 123

Expert Panel Validation 123

Contact Us 123

Disclaimer 124

List of Tables

List of Tables

Number of Products under Development for Burkitt Lymphoma, H2 2016 9

Number of Products under Development for Burkitt Lymphoma – Comparative Analysis, H2 2016 10

Number of Products under Development by Companies, H2 2016 12

Number of Products under Investigation by Universities/Institutes, H2 2016 13

Comparative Analysis by Clinical Stage Development, H2 2016 14

Comparative Analysis by Early Stage Development, H2 2016 15

Products under Development by Companies, H2 2016 16

Products under Investigation by Universities/Institutes, H2 2016 17

Burkitt Lymphoma – Pipeline by AbbVie Inc, H2 2016 18

Burkitt Lymphoma – Pipeline by Arvinas, Inc., H2 2016 19

Burkitt Lymphoma – Pipeline by bluebird bio, Inc., H2 2016 20

Burkitt Lymphoma – Pipeline by Boehringer Ingelheim GmbH, H2 2016 21

Burkitt Lymphoma – Pipeline by Constellation Pharmaceuticals, Inc., H2 2016 22

Burkitt Lymphoma – Pipeline by Immunomedics, Inc., H2 2016 23

Burkitt Lymphoma – Pipeline by Karyopharm Therapeutics, Inc., H2 2016 24

Burkitt Lymphoma – Pipeline by Millennium Pharmaceuticals Inc, H2 2016 25

Burkitt Lymphoma – Pipeline by Patrys Limited, H2 2016 26

Burkitt Lymphoma – Pipeline by Seattle Genetics, Inc., H2 2016 27

Burkitt Lymphoma – Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 28

Burkitt Lymphoma – Pipeline by Theravectys SA, H2 2016 29

Assessment by Monotherapy Products, H2 2016 30

Number of Products by Stage and Target, H2 2016 32

Number of Products by Stage and Mechanism of Action, H2 2016 34

Number of Products by Stage and Route of Administration, H2 2016 36

Number of Products by Stage and Molecule Type, H2 2016 38

Burkitt Lymphoma – Dormant Projects, H2 2016 122

List of Figures

List of Figures

Number of Products under Development for Burkitt Lymphoma, H2 2016 9

Number of Products under Development for Burkitt Lymphoma – Comparative Analysis, H2 2016 10

Number of Products under Development by Companies, H2 2016 11

Number of Products under Investigation by Universities/Institutes, H2 2016 13

Comparative Analysis by Clinical Stage Development, H2 2016 14

Comparative Analysis by Early Stage Products, H2 2016 15

Assessment by Monotherapy Products, H2 2016 30

Number of Products by Top 10 Targets, H2 2016 31

Number of Products by Stage and Top 10 Targets, H2 2016 31

Number of Products by Top 10 Mechanism of Actions, H2 2016 33

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 33

Number of Products by Routes of Administration, H2 2016 35

Number of Products by Stage and Routes of Administration, H2 2016 35

Number of Products by Molecule Types, H2 2016 37

Number of Products by Stage and Molecule Types, H2 2016 37

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared